Masimo (NASDAQ:MASI) Announces Quarterly Earnings Results, Beats Estimates By $0.38 EPS

Masimo (NASDAQ:MASI) released its earnings results on Tuesday. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38, Zacks reports. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million.

Masimo Stock Down 1.6 %

NASDAQ:MASI traded down $2.99 during trading hours on Thursday, hitting $187.48. The stock had a trading volume of 175,353 shares, compared to its average volume of 501,619. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a 1-year low of $101.61 and a 1-year high of $192.62. The business has a 50 day simple moving average of $172.95 and a two-hundred day simple moving average of $153.10. The company has a market cap of $10.04 billion, a PE ratio of 128.99 and a beta of 1.02.

Wall Street Analysts Forecast Growth

MASI has been the subject of several research reports. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday. Wells Fargo & Company lifted their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday. Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.